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The discovery of missense mutations in the gene coding for the Cu/Zn superoxide dismutase 1 (SOD1) in subsets of familial cases was rapidly
followed by the generation of transgenic mice expressing various forms of SOD1 mutants. The mice overexpressing high levels of mutant SOD1
mRNAs do develop motor neuron disease but unraveling the mechanisms of pathogenesis has been very challenging. Studies with mouse lines
suggest that the toxicity of mutant SOD1 is unrelated to copper-mediated catalysis but rather to propensity of a subfraction of mutant SOD1
proteins to form misfolded protein species and aggregates. However, the mechanism of toxicity of SOD1 mutants remains to be elucidated.
Involvement of cytoskeletal components in ALS pathogenesis is supported by several mouse models of motor neuron disease with neurofilament
abnormalities and with genetic defects in microtubule-based transport. Here, we describe how transgenic mouse models have been used for
understanding pathogenic pathways of motor neuron disease and for pre-clinical drug testing.
© 2006 Elsevier B.V. All rights reserved.Keywords: Sclerosis; Mutant SOD1; Toxicity1. Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neuro-
logical disorder that is characterized by the selective loss of
motor neurons leading to progressive weakness, muscle atrophy
with eventual paralysis and death within 5 years of clinical onset.
Approximately 10% of ALS cases are familial, the remainder
ALS cases being diagnosed as sporadic (90%). The discovery a
decade ago of missense mutations in the gene coding for the Cu/
Zn superoxide dismutase 1 (SOD1) in subsets of familial cases
directed most ALS research to elucidating the mechanism of
SOD1-mediated disease. Unraveling the mechanisms of toxicity
of SOD1 mutants has been surprisingly difficult. Nonetheless,
many neuronal death pathways have been revealed through
studies with transgenic mice expressing SOD1mutants. Another
key question in understanding ALS is to what extent cytoskeletal
abnormalities such as intermediate filament (IFs) accumulations,
a hallmark of the disease, actively participate in the neurode-
generative mechanism. Again, transgenic mouse approaches
have been used to clarify the role of IF proteins in motor neuron
death but with complex results. In addition, there is growing⁎ Corresponding author. Tel.: +1 418 654 2704; fax: +1 418 654 2735.
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based transport might be implicated in degeneration of motor
neurons. Here, we will review the mouse studies that contributed
toward understanding the pathogenic pathways of motor neuron
disease and the testing of therapeutic approaches. A list of various
mouse models with motor dysfunction is shown in Table 1.
2. Mice expressing ALS-linked SOD1 mutants
2.1. Toxicity unrelated to copper-mediated catalysis
To date, 114 different mutations have been discovered in the
SOD1 gene that account for ∼20% familial ALS cases [1,2].
SOD1 is an abundant and ubiquitously expressed protein.Because
of its normal function in catalyzing the conversion of superoxide
anions to hydrogen peroxide, it was first thought that the toxicity
of different SOD1 mutants could result from decreased free-
radicals scavenging activity. However, different SOD1 mutants
showed a remarkable degree of variation with respect to
enzymatic activity. Mice expressing mutants SOD1G93A (glycine
substituted to alanine at position 93) or SOD1G37R developed
motor neuron disease despite elevation in SOD1 activity levels
[3]. Moreover, SOD1 knockout mice did not develop motor
neuron disease [4]. The conclusion from these combined results
Table 1
Mouse models with motor neuron dysfunction
Mouse Pathological changes References
Protein misfolding
Mutant SOD1 Loss of 70% spinal motor neurons
IF and SOD1 aggregates
[5–7,
30,31]
Synuclein mutant Perikaryal inclusions and spheroid-like
inclusions of synuclein in motor neurons [119]
Inclusions also abundant in raphe nuclei and
the pons
Intermediate filament disorganization
hNF-H
overexpressor
Perikaryal accumulations and axonal atrophy [60,61]
Altered conductivity but no neuronal loss
mutant NF-L Perikaryal and axonal NF accumulations with
trapped organelles in motor neuron and
sensory neurons
[64]
No degeneration of sensory neurons but
massive degeneration of spinal motor
neurons
NF-L−/− Perikaryal accumulation of NF-M and NF-H [50,56,57]
Developmental loss of 20% motor neurons
Altered nerve conductivity
Mild sensorimotor dysfunction
Peripherin
overexpressor
Age-dependent IF aggregates in perikarya
and axons
[66,67,69]
40% loss of spinal motor neurons
Defects in microtubule-based transport
Dynamitin
overexpressor
Abnormal gaits and decrease in strength
Axonal IF swellings [77]
25% loss of motor axons at 16 months
KIF1B
heterozygous
Staggering gait after 1 year of age [73]
Knockout Progressive muscle weakness
KIF5A knockout NF accumulations especially in sensory
neurons
[75]
Degeneration of sensory axons but not of
motor axons after 5 months
Dynein mutations
heterozygous
Progressive motor dysfunction [78]
Loss of 4 to 70% of motor neurons at
16 months
pmn mouse Axonal swellings and early-onset motor
neuron degeneration
[80,81]
Short tau
overexpressor
Spheroidal inclusions containing tau, NFs
and tubulin
[86]
20% loss of motor axons at 12 months
P25 overexpressor Abnormal tau phosphorylation and
axonopathy
[120]
Others
VEGF ΔHRE Late-onset motor dysfunction [86]
Loss of 40% motor axons at 7 months
Als2 knockout Late-onset degeneration of cerebellar
Purkinje cells
[97,98]
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properties. Unlike transgenic mice overexpressing the wild-type
SOD1, the mice bearing the SOD1G93A, SOD1G37R or SOD1G85R
mutants developed a motor neuron disease with many patholog-
ical changes reminiscent of human ALS [5–7].
Both the nature of the toxicity of SOD1 mutants and the
reason for the susceptibility of motor neurons are not fully
understood. Initially, studies have focused on aberrant copper-mediated catalysis as potential source of toxicity. One hypo-
thesis was that SOD1 mutations enhanced the ability of the
enzyme to use hydrogen peroxide as substrate to generate toxic
hydroxyl radicals that can damage cellular targets including
DNA, protein and lipid membranes [8]. Another hypothesis was
that the misfolding of SOD1 induced by mutations would allow
the access of abnormal substrates such as peroxynitrite to the
catalytic site leading to the nitration of tyrosine residues [9].
However, neither the peroxidase activity nor peroxynitrite hy-
potheses were supported by transgenic mouse studies. The
absence of endogenous SOD1 or the addition of wild-type SOD1
did not affect disease progression in mice expressing mutant
SOD1G85R [10]. Moreover, the gene knockout for the copper
chaperone for SOD1 (CCS) that delivers copper to SOD1 catalytic
site had no effect on disease progression in mutant SOD1
transgenic mice [11]. Finally, transgenic mice overexpressing a
mutant form of SOD1 lacking two of the four histidines residues
coordinating the binding of the Cu at the catalytic site still
developed motor neurodegeneration despite a marked reduction in
SOD1 activity [12]. Thus, the combined studies with genetically
altered mice indicate that SOD1 mutants cause motor neuron
disease through the gain of a new function that is independent of the
enzymatic activity involving the copper catalytic site.
2.2. Complex pathways to motor neuron degeneration
The most prevailing view is that the toxicity of SOD1mutants
is related to the propensity of mutant SOD1 to form noxious
misfolded protein species and aggregates [10–14]. However, the
toxicity of these protein aggregates is still poorly understood.
Deleterious effects could result from the co-sequestering of es-
sential cellular components and from overwhelming the capacity
of the protein folding chaperones [15,16] and/or of ubiquitin pro-
teosome pathway to degrade important cellular regulatory factors
[17]. In cultured neurons, increasing levels of Hsp70 decreased
formation of SOD1 mutant aggregates and toxicity [16]. However,
increasing Hsp70 levels by ∼10-fold did not affect disease
pathology in mice expressing SOD1 mutants [18].
Studies on transgenic mice expressing various SOD1 mutants
suggest that the motor neuron death pathway is complex and that it
involves multiple cascades of events including oxidative damage,
excitotoxicity, alterations in calcium homeostasis, caspase activa-
tion, changes in levels of Bcl-2, mitochondrial defects [19,20] and
Fas transduction [21]. Analysis of mice expressing mutant
SOD1G37R also revealed a deregulation of Cdk5 and Cdk4 activi-
ties in the spinal cord [22,23], which are Cdks with possible
involvement in apoptosis and neurodegeneration ([24,25]. How-
ever, recent studies do not support a role for Cdk5 in pathogenesis
caused by SOD1 mutants. First, the knockout of p35 gene did not
affect disease onset and progression in the SOD1G93A mice [26].
Second, the elimination by gene targeting of the neurofilament
NF-M and NF-H tail domains containing the Cdk5 phosphory-
lations sites conferred protection in SOD1G37R mice, rather than
deleterious effects anticipated from a loss of phosphorylation sink
for Cdk5 activity [27]. One possible explanation for the benefit of
removing the neurofilament tail domains may be an enhancement
of anterograde transport [27] as defects in axonal transport have
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SOD1 [28,29].
Many transgenic mice have been generated in which ALS-
linked SOD1 mutants of different biochemical properties were
expressed. Based on mRNA expression levels established by
Jonsson et al. [30], the rate of synthesis of mutant SOD1 in the
widely used mouse strain SOD1G93A with survival of approx-
imately 130 days corresponds to 40 times the normal synthesis
rate of mouse SOD1. For many other transgenic strains (G85R,
D90A, G93Adl and G127X) with later onset disease, the syn-
thesis rates correspond to approximately 20-fold the synthesis
rate of endogenous SOD1 (Table 2). Thus, very high levels of
mutant SOD1 mRNAs seem required for development of ALS-
like phenotypes within the short life span of mice. Moreover,
the life span of the ALS mice is inversely proportional to gene
dosage. For example, in the SOD1G127X, the survival times in
hemizygous mice was twice as long as in mice homozygous for
the transgene [30]. Yet, the steady-state levels of mutant SOD1
proteins in spinal cords may differ widely between transgenic
mouse strains. The level of human SOD1 protein in the young
G93A strain is of 17-fold higher than normal mouse SOD1
level, whereas the young G85R and G127X mice exhibit levels
that are only 90% and 45% of the mouse SOD1 level [30].
Transgenic mice expressing the mutant SOD1L126Z with mRNA
levels comparable to other ALS mouse models also exhibited
very low levels of mutant SOD1 proteins [31]. Such widely
different steady state protein levels must reflect different sta-
bilities and degradation of the various human SOD1 mutants. It
is noteworthy that despite low human SOD1 protein levels in
the young G85R, G127X and L126Z mice, their life span
remains similar to the G37R or G93A mice that express similar
human SOD1 mRNA levels but with much higher steady state
protein levels at early stages. Nonetheless, the mutant SOD1
mice (G85R, G127X and L126Z) with low-steady state protein
levels showed similar amounts of detergent-insoluble aggre-
gates in the spinal cord at end-stage of disease [7,30,31]. The
combined studies suggest that the motor neuron disease may be
caused by long-term exposure to noxious misfolded mutant
SOD1 species with propensity to aggregate. However, the exact
mechanism of toxicity of the misfolded SOD1 species remains
unknown.
2.3. Involvement of non-neuronal cell types
Pathological analysis of SOD1G93A mice carried out at
various ages at neuromuscular junctions, ventral root and spinal
cord revealed that motor neuron pathology begins at the distal
axon and progresses in a “dying back” pattern [32]. Thus, the
SOD1G93A mice show end plate denervation a long time before
ventral root axons loss and motor neuron loss. The failure to
detect mutant SOD1L126Z proteins in distal nerve fibers of
transgenic mice suggest that direct damage to axons by mutant
SOD1 is not a requirement for such axonal dying back
mechanism [31].
In addition to intrinsic motor neuron death pathways, there is
now compelling evidence that non-neuronal cells might contri-
bute to pathogenic process in mice expressing SOD1 mutants. Intransgenic mice or rats expressing mutant SOD1, there is a
reduction in levels of astroglial glutamate transporter EAAT2 that
may provoke a glutamate-induced excitotoxicity [7,33]. Excess
glutamate can cause neuronal death via abnormal activation of
glutamate receptors, allowing Ca2+ entry into the cell and altering
cytosolic free Ca2+ homeostasis. Moreover, microglial activation
may be involved in the neurodegenerative process. Robust NF-
κB activity and expression of proinflammatory cytokines and
chemokines were detected by in situ hybridization within spinal
cord in SOD1G37R mice [34]. The chronic induction of innate
immunity by intraperitonial injection of lipopolysaccharides
(LPS) exacerbated disease by about 3 weeks in SOD1G37R mice
[35], suggesting that inflammation may contribute to neurode-
generative processes. Conversely, an attenuation of neuroinflam-
mation by minocycline or COX-2 inhibitors extended the
longevity of ALS mice [36,37].
To unravel what cell types produce the deleterious effects
leading to motor neuron death, transgenic mice expressing
SOD1 mutants under astrocyte- or neuronal-specific gene
promoters have been generated. Expression of the SOD1G86R
mutation under the GFAP promoter produced astrocytosis but
no motor neuron disease [38]. Recently, transgenic mice
expressing a SOD1G37R cDNA under the prion gene promoter
were reported to develop motor neuron disease [39]. This
demonstrates that expression of mutant SOD1 in the
neuromuscular unit is sufficient to cause disease and that
expression of mutant SOD1 in microglia is not a requirement
to trigger disease. Surprisingly, neuron-specific expression of
SOD1 mutants with NF-L or Thy1 gene promoters in mice did
not induce motor neuron disease [40,41]. However, the
possibility remained that the level of transgene expression
during aging was below the threshold necessary to provoke
disease. This concern has subsequently been addressed by the
generation of chimeric mice comprised of mixtures of normal
and SOD1 mutant expressing cells [42]. These chimeric mouse
studies with SOD1 mutants have demonstrated that neuro-
degeneration is delayed or eliminated when motor neurons
expressing mutant SOD1 are surrounded by healthy wild-type
cells. Moreover, these studies show evidence of damage to
wild-type motor neurons by surrounding cells expressing
mutant SOD1. Such results emphasize the importance of a
motor neuron milieu, but the mechanism by which the toxicity
of mutant SOD1 may be transferred from one cell to another is
still unclear.
2.4. Chromogranin-mediated secretion of SOD1 mutants
A search for proteins that interact with mutant SOD1 led to
the recent discovery that chromogranins are interacting with
mutant forms of SOD1, but not wild-type SOD1 [43]. The
chromogranins, namely chromogranin-A (CgA) and chromo-
granin-B (CgB), are soluble, acidic glycophosphoproteins and
are major constituents of secretory large dense-core vesicles
(LDCV) in neurons and endocrine cells. The studies show that
CgA and CgB, which are abundant proteins in motor neurons
and interneurons, may act as chaperone-like proteins to
promote secretion of misfolded SOD1 mutants. Moreover,
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microgliosis and motor neuron death. Such pathogenic
mechanism in ALS based on toxicity of secreted SOD1 mutant
would be consistent with findings that the disease is not strictly
autonomous to motor neurons and that toxicity is transferable
from one cell to another.
3. Mice with disorganized IFs
Neurofilament and peripherin proteins are two types of IFs
detected in the majority of axonal inclusion bodies, called spher-
oids, inmotor neurons ofALSpatients [44,45].Multiple factors can
potentially cause the accumulation of IF proteins including dere-
gulation of IF protein synthesis, proteolysis, defective axonal
transport, abnormal phosphorylation, and other protein modifica-
tions. Evidence for neurofilament involvement in disease came
from the discovery of codon deletions or insertion in the KSP
phosphorylation domain of the neurofilament NF-H gene in a small
number of sporadic ALS patients (∼1% cases) [46] and from the
report of mutations in the rod domain of the NF-L gene in cases of
Charcot–Marie–Tooth disease type 2 [47,48]. Recently, a peri-
pherin frameshift mutation has also been reported in a case of ALS
[49].
3.1. IF gene knockout mice
In the past decade, genetic manipulation in mice has been
used to address the role of neurofilament and peripherin proteins
in neuronal function and disease. Mice knockout for any of the
neuronal IF proteins, i.e., neurofilament proteins, peripherin or
α-internexin, do not develop gross developmental defects or
motor neuron disease [50–55]. Yet, IF deficiencies are not
completely innocuous. The reduction in caliber of myelinated
axons lacking NF-L was accompanied by 50% reduction in
conduction velocity [56], a feature that would be very
deleterious for large animal species. The NF-L null mice
exhibited mild sensorimotor dysfunction and spatial deficits, but
without overt signs of paresis [57]. Moreover, altered cytochrome
oxidase activity in numerous hindbrain regions has been detected in
the NF-L null mice [58]. Significant loss of motor axons has also
been observed in theNF-L null mice [50] and in double NF-M/NF-
H knockout mice [53,55].
In peripherin knockout mice, the number and caliber of myeli-
natedmotor and sensory axons in the L5 roots remained unchanged
but there was a substantial reduction (∼ 34%) in the number of L5
unmyelinated sensory axons, demonstrating a requirement of peri-
pherin for the proper development of a subset of sensory neurons
[59].
3.2. Neurofilament overexpressors
The overexpression in mice of any of the three wild-type
neurofilament subunits alone can provoke the accumulation of
neurofilaments in neuronal cell bodies [60,61]. For example,
high-level expression of human NF-H proteins cause large
perikaryal neurofilament accumulations. The sequestration of
neurofilaments in cell body resulted in atrophy of motor axonsand altered axonal conductances but without motor neuron death
even in two-year old mice [63]. Surprisingly, overexpressing
NF-L in NF-H transgenic mice reduced the perikaryal swellings
and rescued the motor neuron dysfunction illustrating again the
importance of subunit stoichiometry for proper neurofilament
assembly and transport [62]. The proof that neurofilament
abnormalities can induce neuronal death came from the expression
of an assembly-disrupting NF-L transgene having a Leucine to
Proline substitution near the end of the conserved rod domain [64].
Mice expressing this NF-L mutant at only 50% of the endogenous
NF-L level exhibited within 4 weeks after birth a massive loss of
motor neurons. However, the exact mechanism of toxicity of
mutant NF-L is not yet fully understood. Increasing the levels of
bcl-2 did not protect the large motor neurons from the toxicity of
mutant NF-L [65].
3.3. Peripherin abnormalities
The sustained overexpression of wild-type peripherin in
mice caused the selective loss of motor neurons during aging
[66,67]. The onset of neuronal death was precipitated by the
absence of NF-L, as revealed by cross-breeding of peripherin
transgenic mice with NF-L knockout mice. This context is
reminiscent of the findings in ALS in which there is a
reduction of NF-L mRNA levels in affected motor neurons
[68]. In addition, it induced formation of perikaryal and axonal
IF inclusions resembling spheroids in motor neurons of human
ALS. The toxicity of peripherin overexpression in mice may
be related in part to the axonal localization of IF aggregates.
This is supported by the rescue of peripherin-mediated disease
in mice by the overexpression of NF-H transgene [69]. A
reasonable explanation is that perikaryal sequestering of
excess peripherin protein reduces the formation of deleterious
axonal IF accumulations. Other mechanisms may also
contribute to the toxicity of peripherin overexpression. In
vitro studies have shown that dorsal root ganglion (DRG)
neurons from peripherin transgenic embryos die when grown
in a proinflammatory CNS culture environment rich in
activated microglia [70], suggesting that peripherin aggregates
might predispose neurons to deleterious effects of a proin-
flammatory environment. To investigate the role of peripherin
in disease caused by SOD1 mutations, SOD1G37R mice that
lack peripherin or that overexpress peripherin have been
generated [71]. The excess or absence of peripherin did not
affect the onset and progression of motor neuron disease in
mutant SOD1 mice. Thus, it can be concluded that peripherin
is not a key contributor of motor neuron degeneration
associated with toxicity of mutant SOD1. Nevertheless,
because mutations in SOD1 are responsible for only ∼2% of
all ALS cases, it remains possible that peripherin might
contribute to motor neuron loss in ALS of other etiologies.
Further support for the peripherin involvement in disease came
from the findings of toxic peripherin splicing variant [72] and
from the discovery of a frameshift mutation in the peripherin
gene of a human ALS case [49]. This mutation in exon 1
predicts the production of a truncated protein of 76 amino acids of
the peripherin head domain. Because this peripherin species lacks
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is surprising that transfection experiments with the frameshift
mutant PRPH228delC in SW13 cells caused disruption of neu-
rofilament network assembly. Future studies with transgenic mice
bearing this PRPH frameshift mutant might provide new insights
into the molecular mechanisms of motor neuron disease.
4. Mice with defects of microtubule-based transport
Axonal transport is essential to neurons because of the
extreme polarity and size of these cells. In humans, spinal motor
neurons may have axons of more than 1 meter in length. Most
proteins must be synthesized in cell bodies and transported to
nerve terminals through axonal transport. Various molecular
motors, which are multi-subunit ATPases members of the
kinesin family and dynein, move cargos along microtubules in
the anterograde and retrograde directions, respectively. Impair-
ment of axonal transport has recently emerged as a common
factor in several neurodegenerative disorders. Mutations that
disrupt either kinesin or the dynein complex cause impairment of
axonal transport, blockade of membranous cargoes and axonal
degeneration.
4.1. Kinesins
The creation of mice heterozygotes for disruption of the
kinesin KIF1B gene provided the proof that defects in axonal
transport can provoke neurodegeneration [73]. These mice
showed defect in transporting synaptic vesicle precursors and
they suffer from progressive muscle weakness similar to
human neuropathies. This discovery subsequently led to the
identification of a loss-of-function mutation in the motor
domain of the KIF1B gene in patients with Charcot–Marie–
Tooth disease type 2A [73]. In addition, missense mutations
in the conventional KIF5A are responsible for a hereditary
form of spastic paraplegia [74] and disruption of KIF5A gene
in mice was reported to cause neurofilament transport
impairment [75].Table 2
Different steady-state protein levels in mice expressing various mutant SOD1
transgenes
Mouse
strain
hSOD1 mRNA
levels relative to
mouse SOD1
Spinal cord protein
levels relative to mouse
SOD1 in young mice
Life
span
References
In vivo stable SOD1 mutants
G93A 40 17 124 days [30]
G93Adl 20 8 253 days [30]
D93A 20 20 407 days [30]
G37R
line 29
– 5 365 days [6]
G37R
line 42
– 12 154 days [6]
In vivo unstable SOD1 mutants
G85R 17 0.90 345 days [7,30]
G127x 25 0.45 250 days [30]
L126Z high low 210 days [31]4.2. Dynein
Dynein is a molecular motor involved in retrograde axonal
transport of organelles along microtubules. Dynein activity
requires association with dynactin, a multiprotein complex that
activates the motor function of dynein and participates in cargo
attachment [76]. The overexpression of the p50 subunit of
dynactin, dynamitin, disrupts the dynein/dynactin complex
thereby inhibits motor activity. Transgenic mice overexpressing
dynamitin developed a late-onset and progressive motor neuron
disease resembling ALS with neurofilamentous swellings in
motor axons [77]. Other mouse mutants, called legs at odd
angles (Loa) and cramping 1 (Cra1) that arose by mutagenesis
with N-ethyl-N-nitrosourea, were found to carry missense
mutations the dynein heavy chain 1 gene [78]. The Loa and
Cra1 mice bearing heterozygous dynein mutations develop
progressive motor neuron due to impairment in retrograde
transport. The notion that impairment of retrograde axonal
transport may play causative role in pathogenesis is further
supported by the discovery of missense mutations in the
dynactin/p150glued cause a lower motor neuron disease in
humans [79].
4.3. The pmn mouse
Mice that are homozygous for the pmn mutation develop a
progressive caudio-cranial degeneration of their motor axons
from the age of 2 weeks and die four to 6 weeks after birth. This
autosomal recessive disease was discovered by spontaneous
mutation in mice. Evidence for the importance of the axonal
transport machinery in motor neuron disease came from the
identification the gene mutation responsible for the pmn in the
mouse. Two groups identified the pmn mutation as a Trp to Gly
substitution at the last residue of the tubulin-specific chaperone
(Tbce) protein [80,81]. The Tbce is essential for proper tubulin
assembly and for the maintenance of microtubules in motor
axons. This suggests that altered function of tubulin cofactors
might be implicated in human motor neuron diseases.
4.4. Tau
Tau is a microtubule-associated protein involved in stabili-
zation of microtubules. There are six tau isoforms that are
derived from a single gene via alternative splicing of the
primary gene transcript. Abnormalities of tau in human disease
are known as tauopathies that include Alzheimer's disease
(AD), frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), progressive supranuclear palsy
(PSP) and amyotrophic lateral sclerosis/parkinsonism–demen-
tia complex of Guam [82]. Transgenic mice overexpressing the
shortest tau isoform developed axonal degeneration of spinal
neurons and motor weakness [83]. These tau transgenic mice
are characterized by the presence of filamentous aggregates of
hyperphosphorylated tau, not only in cortical and brain stem
neurons, but also in spinal neurons [84]. The inclusions contain
10- to 20-nm tau-positive straight filaments. Gliosis has been
detected in the spinal cord with degeneration of axons in ventral
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demonstrating that abnormalities in tau protein can directly
affect neurofilaments. Breeding experiments with tau transgenic
mice and NF-L knockout mice revealed an alleviation of tau-
mediated disease by reducing the neurofilament content [85].
5. Mice with targeted disruption of hypoxia response
element
Vascular endothelial growth factor is a cytokine crucial for
angiogenesis. Targeted disruption in mice (VEGFδ/δ) of the
hypoxia response element sequence in the vascular endothelial
growth factor gene resulted in severemotor deficits at 5–7months
of age with pathological changes resembling ALS such as
neurofilament accumulations in the spinal and brainstem motor
neurons [86]. The mechanism of disease is still unclear. It has
been suggested that chronic vascular insufficiency and possibly a
lack of VEGF neuroprotection might result in motor neuron
degeneration. The SOD1G93A mice crossed with VEGFδ/δ mice
die earlier because of more severe motor neuron degeneration
[87]. Some studies found an association of that some human
haplotypes in the VEGF upstream promoter sequence with risk of
ALS [87,88] and there is evidence for a VEGF deregulation in
response to hypoxia in patients with ALS [89].
6. The wobbler
The wobbler mouse in another model of motor neuron disease
which has been extensively investigated [90]. The wobbler mice
originated from a spontaneous mutation that is transmitted by an
autosomal recessive gene wr mapping to chromosome 11. How-
ever, the exact genetic defect has not yet been identified. The
symptoms of wobbler mice can be recognized early in the post-
natal period. The disease is associated with the degeneration and
loss of spinal motor neurons. Pathology of cortical motor neurons
has also been reported [90]. The wobbler phenotype is character-
ized by perikaryal vacuolar degeneration and swelling of motor
neurons, astrogliosis and microglia activation. There is evidence
of dysfunctional mitochondrial respiration in the wobbler with
decreased activity of complex IV in a manner similar to what has
been reported in the spinal cord of patients with sporadic ALS
[91]. Ubiquitin and hyperphosphorylated NF-H immunoreactiv-Fig. 1. Electron microscopy reveals degenerating axons (arrows) in corticospinal tract
of age.ities have also been detected in cortical neurons of affected ani-
mals [92].Moreover, increased expression of neurofilamentNF-M
protein has been observed in affectedmotor neuron in the wobbler
mice [92]. To what extent the NF-M overexpression contributes to
pathogenesis remains unknown. In future, it would be of interest to
use the NF-M knockout mice to address this question.
7. Mice knockout for Als2
Deletion mutations were discovered in coding exons of a
new gene mapping to chromosome 2q33, ALS2 coding for
Alsin, from patients with an autosomal recessive form of
juvenile ALS (JALS), primary lateral sclerosis and infantile-
onset ascending hereditary spastic paralysis (IAHSP) [93–96].
The ALS2 gene is ubiquitously expressed. It encodes a protein
having guanine nucleotide exchange factor (GEF) homology
domains which are known to activate small guanosine tripho-
sphatase (GTPase) belonging to the Ras superfamily. The
RCC1-like, DH/PH and VPS9 domains are GEF for small
GTPase Ran (Ras-related nuclear), Rho (Ras-homologous
member) and Rab5 (Ras-related in brain 5), respectively.
Als2 knockout mice have been reported recently by two
groups [97,98]. These studies demonstrate that absence of Als2
does not produce a severe phenotype in mice. However, the
studies by Cai et al. [97] showed that the Als2 null mice develop
age-dependent deficits in motor coordination and primary motor
cultured motor neurons lacking Als2 were more susceptible to
oxidative stress. Whereas Cai et al. detected no neuropatholog-
ical changes in their Als2 null mice, Hadano et al. [98] showed
that Als2-null mice develop an age-dependent and slow
progressive loss of cerebellar Purkinje Cells, a reduction in
ventral motor axons during aging, astrogliosis and evidence of
deficits in endosome trafficking. Our laboratory also generated
a mouse knockout for Als2 using a targeting vector by replacing
exon 2 and part of exon 3 with a 1.1 kb Neo cassette (Kriz J,
Millecamps S, Urushitani M, Zhu Q and Julien JP, unpublished
results). In agreement with the two other groups, our Als2
knockout mice developed only mild motor dysfunction as
determined by rotarod test. Nonetheless, electron microscopy
(EM) provided evidence of pathological changes. In 18-month-
old Als2 null mice, EM revealed the presence of degenerating
axons in corticospinal tracts (Fig. 1). So, it is anticipated that theof Als2 null mice (Als2−/−) as compared to a normal mouse (WT) at 18 months
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be useful to investigate some aspects of Als2 functions in
endosomal trafficking and the long-term vulnerability of large
neuronal subsets to degeneration.
8. Testing therapeutic strategies in mice expressing mutant
SOD1
Presently, there is no effective pharmacological treatment for
ALS. Transgenic animal models that exhibit many of the
pathological changes in human ALS provide useful tools for
drug testing. Table 3 lists some of the genetic manipulations and
drugs tested in mice expressing SOD1 mutants. Many of the
pharmacological approaches tested so far have produced only
modest beneficial effects. Vitamin E, gabapentin and salicylate
had no effect on survival of SOD1G93A mice [99–101]. Riluzole,
a glutamate antagonist and the only drug currently approved for
ALS treatment, extended the life span of SOD1G93A mice by 10–
15 days without affecting disease onset. More neuroprotectionTable 3
Therapeutic interventions in animals expressing mutant SOD1
ALS
mouse
Increased life
span
References
Pharmacolocigal Treatments
Creatine (diet) SOD1G93A 20 days [115]
Riluzole (diet) SOD1G93A 10–15 days [100]
Gabapentin (diet) SOD1G93A no effect [99]
Vitamin E (diet) SOD1G93A no effect [99]
Lysine Acetyl-salicylate (diet) SOD1G93A no effect [130]
Minocycline (diet) SOD1G37R 21–35 days [36,103,104]
SOD1G93A 11–21 days
Cocktail of
Minocycline-riluzole-nimodipine
SOD1G37R 42 days [105]
Ceftriaxone SOD1G93A 10 days [106]
Ginseng SOD1 G93A 7 days [121]
zVAD-fmk (i.c.v.) SOD1G93A 27 days [102]
SOD1 injection SOD1G93A 24 days [122]
AOL 10150 SOD1G93A 20 days [107]
Transgene overexpression
Human NF-H SOD1G37R 2–4 months [125]
Bcl-2 SOD1G93A 30–35 days [126]
Dominant inhibitor of caspase-1 SOD1G93A 27 days [127]
Gene knockout
NF-L−/− SOD1G85R 6 weeks [22,128]
SOD1G37R 10–15 weeks
Tailess NFH and NFM SOD1G37R 8 weeks [27]
Peripherin −/− SOD1G37R No change [71]
nNOS−/− SOD1G93A No change [129]
Il-1beta −/− SOD1G37R No Change [34]
CCS−/− SOD1G85R No change [11]
SOD1G37R
SOD1G93A
Viral gene therapy
IGF1 SOD1G93A 37 days [110]
GDNF SOD1G93A 25 days [123]
VEGF SOD1G93A 40 days [111]
Cardiotrophin SOD1G93A 27 days [124]
RNAi SOD1G93A 100 days [112–114]was provided in SOD1G93A mice by the intra-cerebroventricular
administration of N-Benzyloxycarbonyl–Val–Ala–Asp–fluoro-
methylketone (zVAD-fmk), a broad caspase inhibitor [102].
Celecoxib treatment significantly delayed the onset of weakness
andweight loss and prolonged survival by 25% [37]. Celecoxib is
an inhibitor of cycloxygenase 2 (COX-2), an enzyme that plays a
role in inflammatory processes and in production of prostaglan-
dins that can stimulate the release of glutamate from astrocytes.
Minocycline, a second-generation tetracycline with anti-in-
flammatory properties, has been shown to increase survival in at
least three independent laboratories, using two different mutant
SOD1 mouse lines, and using various modes of drug delivery
[36,103,104]. Minocycline may confer neuroprotection by
multiple pathways as it can reduce microglial activation,
caspase-1, caspase-3, iNOS, p38 MAP kinase and mitochondrial
cytochrome c release. Moreover, the addition of riluzole and
nimodipine further enhanced the effect ofminocycline on survival
[105]. Minocycline is a clinically well-tolerated drug. There is an
on-going human trial to test the effectiveness of minocycline in
ALS. Another antibiotic, the beta-lactam antibiotic ceftriaxone,
can confer certain protection in mouse model of ALS presumably
through elevation of expression of glutamate transporter EAAT2
(also calledGLT-1) [106]. An elevation in EAAT2would attenuate
glutamate neurotoxicity. A clinical trial is also in progress to test the
efficacy of ceftriaxone in humanALS. Another compound that can
catalytically decompose oxidants as peroxynitrite, the manganese
porphyrin AEOL 10150, was found to extend the survival of
SOD1G93A mice by approximately 20 days when administered
intra-peritoneally or subcutaneously at symptom onset [107].
Apoptotic pathways might represent targets for disease
intervention in ALS. Thus, many neurotrophic factors such as
IGF-1, GDNF, CNTF and VEGF might confer protection to
motor neurons. The failure of neurotrophic factors in human trials
so far may be due in part to the limited delivery of the proteins to
the target neurons. Recently, the intracerebroventricular delivery
of recombinant VEGF was found to delay disease onset and to
extend survival in a SOD1G93A rat model [108]. Another ap-
proach for treatment of motor neuron disease that may be con-
sidered for future would involve the delivery of viral vectors to
mediate expression of either growth factors such GDNF, IGF-1
and VEGF [109–111]. Another strategy for treatment of familial
ALS cases would be to use viral vectors encoding RNAi
molecules to target SOD1 mRNA for degradation [112–114].
Remarkably, SOD1 silencing with lentiviruses almost doubled
the longevity of mice expressing SOD1G93A mutant [112].
Yet,mice are not humans and sometimes therapeutic approaches
that confer benefits with mouse models might fail in a human trial.
A good example is creatine, a compound believed to improve
mitochondrial function. Creatine administered in drinking water
was found to extend the longevity ofmice expressingmutant SOD1
[115,116]. However, a clinical trial of creatine was found to be
ineffective in human ALS [117]. So, the results in mouse models
should be interpreted with caution. Many factors must be
considered including pharmacokinetics, as well as routes and
timing of drug administration. There is also the question of validity
of themutant SOD1mice asmodels of gene defects that account for
only 2% of ALS cases.
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Despite important effort devoted in the past decade toward
elucidating the mechanism of disease caused by SOD1
mutations, the neurodegeneration mechanism is still not fully
understood. The SOD1 mutants cause disease through acqui-
sition of toxicity. Yet, it is not resolved how SOD1 mutants can
trigger through protein misfolding some death pathways
selectivity in neuronal subsets. There is evidence that patho-
genic SOD1 mutants can form pore-like oligomeric structures
[131]. Whether mutant SOD1 aggregates can permeabilize
membranes through formation of ion channels is an intriguing
possibility that merits to be considered.
In light of the emerging evidence for a crucial role of axonal
transport in motor neuron disease, there is a need to clarify the
cytoskeletal changes associated with human ALS. The
abnormal IF accumulations, a hallmark of ALS, emerged as
intrinsic factors that may affect the disease either negatively or
positively. Yet, the mechanisms underlying the formation and
neurotoxicity of IF accumulations are not fully understood.
Disorganization of IF network could result from a variety of
primary causes including neurofilament gene mutations,
deregulation of IF gene expression, post-translational modifica-
tions and axonal transport defects. Motor neuron loss has been
observed in some transgenic mouse models exhibiting an
axonal localization of IF swellings supporting the view of
“axonal strangulation” disease model by which IF swellings can
block axonal transport [2,3]. Other toxic mechanisms may also
be involved. For instance, in vitro culture studies suggest that
peripherin aggregates can predispose neurons to apoptotic death
induced by a proinflammatory CNS environment [70]. Thus,
the presence of IF aggregates may sometimes lower the
threshold to neuronal death in a toxic environment.
A key role of axonal transport in pathogenesis of motor neuron
disease was recently supported by the inhibition of molecular
motors in transgenic mice. Therefore, studies on the neuronal
cytoskeleton and molecular motors of the microtubule-based
transport might offer promising research avenues to understand
the selective vulnerability of motor neurons to disease.
Although intracellular dysfunction such as axonal transport
defects may cause motor neuron degeneration, there is evidence
that the disease is not strictly cell autonomous in mutant SOD1
models. Chimeric mouse studies suggested that non-neuronal
cells are involved in the disease process but the molecular
mechanisms in various cell types that contribute to motor
neuron death remain to be elucidated [42]. Recent findings
demonstrated that chromogranins can interact selectively with
mutant forms of SOD1 to promote secretion of these molecules
[43]. Extracellular mutant SOD1 and chromogranin A can
trigger microglial activation and death of motor neurons in
culture. If extracellular SOD1 mutant contributes to pathogen-
esis, there is a rationale to develop approaches for clearance of
extracellular SOD1 mutant. Moreover, in mutant SOD1 mice,
there is an enhanced signal for chromogranin A in activated
astrocytes. It has been suggested that a potential implication of
enhanced chromogranin levels is that the N-terminal peptides of
chromogranin A can act on blood vessels as antiangiogenicagents [118]. Perhaps, this action would be counteracted with
VEGF treatment. Whether alteration in the vasculature of spinal
cord contributes to ALS pathogenesis is another question that
remains to be explored. In future, it will be of interest to
generate mutant SOD1 mice in context of deficiency or excess
of chromogranin expression.
Another question is whether results of drug testing in ALS
mouse models are predictive of human outcomes. Is the widely
used SOD1G93A mouse strain a valid pre-clinical model for drug
testing? The synthesis rate of human SOD1mutant in this mouse
corresponds to 40 times the synthesis of endogenous mouse
SOD1. It has been proposed that extreme levels of mutant SOD1
proteins in such mouse models can produce artifacts such as
vacuoles, which may not be relevant to human ALS pathogen-
esis [30]. Perhaps, it would be more appropriate to consider
testing of therapeutic approaches and potential drugs in
experimental models with late onset of disease that mimic better
the human situation, i.e., with lower gene copy number encoding
the mutant SOD1 proteins. For example, overexpression of a
human NF-H transgene extended the life span by several months
in mice from line 29 overexpressing SOD1G37R by 5-fold but
these same the hNF-H transgene had little effect in mice of line
42 overexpressing SODG37R by 12-fold [22].
In view of the complexity of the disease, a combination of
different therapies acting in synergy will probably be needed for
effective ALS treatment. In a near future, new strategies might
include a search for agents that can prevent the abnormal
aggregation of proteins, mutant SOD1 or IF proteins. As more
associated genes are discovered, new therapeutic approaches
could potentially be derived. Gene therapy approaches
involving the use of recombinant viruses offer a promising
strategy for the delivery of genes to enhance motor neuron
survival or to silence specific deleterious genes such as mutant
SOD1. The next few years should also provide some perspective
on the potential of neural stem cells to replace or to repair damaged
neurons. Finally, a better understanding of ALS pathogenesis
through the use of animal models and the development of efficient
therapeutics will require the discovery of new genes and
biomarkers associated with the disease, especially for sporadic
ALS cases.
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